2,749
Views
2
CrossRef citations to date
0
Altmetric
Meningococcal – Research Paper

Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database

Article: 2021764 | Received 08 Sep 2021, Accepted 19 Dec 2021, Published online: 22 Feb 2022

Figures & data

Table 1. Age distribution of the cases

Figure 1. Patient trajectory for management of invasive meningococcal disease. For one patient, discharge destination was unknown.

Figure 1. Patient trajectory for management of invasive meningococcal disease. For one patient, discharge destination was unknown.

Table 2. Characteristics of index hospitalization stay, by age group

Table 3. Hospital stay duration and in-hospital mortality in children, adolescents, and young adults during the six-year study period

Figure 2. Mortality risk as a function of age in survivors. Hazard ratios for mortality (excluding death during the index hospitalization) in cases compared to controls are presented with their 95% confidence interval.

Figure 2. Mortality risk as a function of age in survivors. Hazard ratios for mortality (excluding death during the index hospitalization) in cases compared to controls are presented with their 95% confidence interval.

Table 4. Hospitalizations in cases and controls during the follow-up period

Table 5. Sequelae of interest

Figure 3. Sequelae of interest. Data are presented as a Forest plot illustrating the risk ratios for the occurrence of each type of sequela between cases and controls, with their 95% confidence intervals (95% CI).

Figure 3. Sequelae of interest. Data are presented as a Forest plot illustrating the risk ratios for the occurrence of each type of sequela between cases and controls, with their 95% confidence intervals (95% CI).

Table 6. Frequency of sequelae as a function of age class

Table 7. Association between number of sequelae and proportion of patients hospitalized or death

Figure 4. Graphical plain language summary.

Figure 4. Graphical plain language summary.
Supplemental material

Supplemental Material

Download MS Word (18.9 KB)

Data availability statement

GSK makes available anonymized individual participant data and associated documents from interventional clinical studies that evaluate medicines upon approval of proposals submitted to www.clinicalstudydatarequest.com. To access data for other types of GSK sponsored research, for study documents without patient-level data and for clinical studies not listed, please submit an inquiry via the website.